Restasis is a prescription cyclosporine ophthalmic emulsion approved by the FDA to treat chronic dry eye with decreased tear production due to inflammation. Manufactured by Allergan, an AbbVie company, it targets the immune-driven root cause of the condition rather than simply lubricating the surface of the eye.
The active ingredient, cyclosporine 0.05%, limits T-cell activity and suppresses inflammatory enzymes in the lacrimal glands. Clinical trials show significant tear production increases at 6 months of consistent use. User reviews are deeply split: 26-42% report meaningful positive results while many others cite severe burning, high cost, and no measurable relief after 1 to 2 years of use.
This review covers how Restasis works, what the clinical evidence shows, what real patients report, how it compares to Xiidra, and whether the cost is worth it. For some patients with severe inflammation-driven dry eye, it is life-changing. For others, alternatives prove more effective.
What Is Restasis Eye Drops?
Restasis is a prescription ophthalmic emulsion containing 0.05% cyclosporine, developed by Allergan, an AbbVie company, to treat chronic dry eye with decreased tear production caused by ocular surface inflammation. Here’s the thing: it’s not a lubricating eye drop. It’s not a substitute for artificial tears either. The drug targets the immune-driven root cause of the condition.
Restasis belongs to the drug class known as topical immunomodulators. That’s an important distinction. Cyclosporine, the active ingredient, suppresses the immune response in the lacrimal glands. This separates it from standard over-the-counter dry eye products that simply add surface moisture.
The FDA approved Restasis for patients 16 years and older diagnosed with keratoconjunctivitis sicca. That’s the clinical term for chronic dry eye with decreased tear production. It’s a prescription-only medication, which means you can’t just pick it up off the shelf.
What Does Restasis Treat?
Restasis treats keratoconjunctivitis sicca, the medical term for chronic dry eye characterized by reduced tear production due to ocular surface inflammation. In plain English: it targets the kind of dry eye that happens when your immune system attacks your own tear glands. It’s also prescribed for dry eye related to Sjogren’s syndrome.
Sjogren’s syndrome is a chronic autoimmune disorder that attacks the lacrimal and salivary glands. About 1 in 10 people with lupus has it. People with Sjogren’s often experience a gritty or sandy sensation in the eyes, especially in the morning.
Elevated inflammatory cytokines, including IL-2, IL-6, IL-8, and TNF-alpha, have been found in the tears of dry eye patients. Why does this matter? Because it confirms that dry eye in these patients isn’t just a surface problem. It’s a systemic immune response happening in the glands. Restasis works by reducing this inflammatory signaling process directly.
How Does Restasis Work?
Cyclosporine works as a topical immunomodulator by limiting T-cell activity and suppressing the production of inflammatory enzymes in the lacrimal glands, which allows tear-producing tissue to recover its natural function. Think of it this way: steroid drops put out the fire broadly; Restasis targets the specific immune cells starting it. That’s a meaningful difference in how each drug works.
Restasis reduces inflammation at the ocular surface without the systemic immunosuppression associated with oral cyclosporine. And here’s an interesting secondary finding: patients treated with cyclosporine had fewer microbes on their ocular surface compared to vehicle-treated patients.
The emulsion formulation exists because cyclosporine has poor water solubility. Restasis uses castor oil and other emulsifiers to keep the drug stable and bioavailable. The vial must be inverted several times before use to achieve a uniform white opaque emulsion.
What Are the Ingredients in Restasis?
Restasis contains cyclosporine 0.05% (0.5 mg/mL) as the active ingredient, a cyclic polypeptide immunosuppressant with the molecular formula C62H111N11O12 and a molecular weight of 1202.6. In pure form, cyclosporine is a fine white powder. Once formulated into Restasis, it becomes a white opaque to slightly translucent emulsion.
The inactive ingredients are equally important. Can’t Restasis just be a simple water solution? No. Cyclosporine doesn’t dissolve in water, so the emulsion base is essential. The emulsion has a pH of 6.5 to 8.0 and osmolality of 230 to 320 mOsmol/kg, keeping it compatible with the eye’s natural chemistry.
Full Ingredient List:
- Cyclosporine 0.05% — active ingredient
- Glycerin 2.2%
- Castor oil 1.25%
- Polysorbate 80 1.00%
- Carbomer copolymer type A 0.05%
- Purified water
- Sodium hydroxide (for pH adjustment)
How Is Restasis Formulated?
Restasis is formulated as an oil-in-water emulsion rather than a standard solution because cyclosporine has extremely poor water solubility, requiring a lipid-based carrier system to remain stable and bioavailable in the eye. Here’s why this matters: the emulsion must be shaken before each use to maintain uniform drug distribution throughout the liquid. Skip that step and you get an uneven dose.
Compounded cyclosporine versions exist in concentrations of 0.5%, 1%, and 2%. These higher concentrations are used in countries where Restasis is unavailable or by patients who need stronger doses. The 2% compounded form uses sterile olive or corn oil as the base due to tolerability issues with high-alcohol injectable-grade formulations.
What Are the Benefits of Restasis?
Restasis increases the eyes’ natural ability to produce tears by treating the underlying inflammatory cause of chronic dry eye, rather than simply adding temporary moisture with artificial lubricants. The good news? For patients with immune-driven dry eye, this is the difference between treating the cause and managing a symptom. OTC drops do the latter; Restasis attempts the former.
Long-term consistent use is required to realize the full benefit. How long is ‘long-term’? For most patients, that means indefinitely. Stopping the drug typically brings symptoms back. Clinical data shows statistically significant improvement in tear production at the 6-month mark, and some patients report sustained relief as long as treatment is maintained.
Key Benefits of Restasis:
- Treats the root cause of inflammation-driven dry eye
- Increases natural tear production over time
- Can be used long-term for sustained management
- Compatible with artificial tears (allow a 15-minute interval)
- Clinically studied with measurable outcomes at 6 months
Does Restasis Increase Tear Production?
Yes. Restasis demonstrated a statistically significant increase in tear production at 6 months in clinical trials, measured by Schirmer test scores comparing Restasis users to patients receiving the vehicle emulsion without the active drug. Early signs of improvement can appear at the 3-month mark for some patients. Individual results vary, and not everyone responds.
Does it work for everyone? No. Restasis did not increase tear production in patients already using topical anti-inflammatory drugs or tear duct plugs. Patients with dry eye caused by non-inflammatory factors may see limited benefit.
Stopping Restasis typically results in a full return of dry eye symptoms. This confirms that the drug manages the condition rather than curing it. Long-term use is generally expected for patients who respond well.
To be clear: Restasis treats the inflammation, not the dryness itself. Cyclosporine reduces the production of inflammatory enzymes and limits T-cell activation in the lacrimal gland. In fact, patients treated with cyclosporine showed fewer microbes on their ocular surface compared to vehicle-treated patients, suggesting a secondary antimicrobial benefit as well.
What Do Restasis Reviews Say?
Restasis has deeply mixed user reviews, with ratings of 4.6 out of 10 on Drugs.com (227 reviews, 26% positive) and 2.8 out of 5 on WebMD (399 reviews, 42% positive), reflecting a sharp divide between patients who call it life-changing and those who report no benefit at all. So what do patient reviews actually tell us? That Restasis works well for some and does nothing for others. The split is real and documented across multiple platforms.
Rating Overview by Platform:
| Platform | Avg. Rating | Reviews | % Positive |
| Drugs.com | 4.6/10 | 227 | 26% |
| WebMD | 2.8/5 | 399 | 42% |
What Do Positive Restasis Reviews Report?
Positive reviewers describe significant relief from severe chronic dry eye symptoms, including reduced morning eye stickiness, the ability to wear contact lenses again, and an overall return to normal daily eye comfort after years of failed OTC treatments. One reviewer reported 80% improvement after just 3 weeks. And here’s the kicker: many of these patients had given up on ever finding relief before Restasis.
Patients with the most dramatic positive outcomes often had severe underlying conditions such as corneal scarring, ocular rosacea, or Sjogren’s syndrome. They had tried lubricants, fish oil supplements, compresses, and humidifiers before finding relief. So the pattern is clear: the worse the underlying inflammation, the more likely Restasis produces a dramatic turnaround.
What Are the Common Complaints About Restasis?
Negative reviewers most frequently cite severe burning pain during application (described as beyond mild discomfort), the high out-of-pocket cost, and the notoriously poor design of the Restasis multidose bottle, which multiple users including experienced nurses describe as ‘user-hostile.’ Here’s what no one tells you: the pain complaint isn’t rare. It dominates the negative experience across platforms.
The multidose bottle receives specific criticism for requiring excessive squeezing force, often dispensing 3 drops when only 1 is needed. The thick plastic casing and short nozzle pose particular difficulty for older patients and those with arthritis or hand weakness. Multiple reviewers ask why the design hasn’t changed despite years of feedback.
A significant portion of negative reviewers report no measurable improvement after 1 to 2 years of consistent use. Some switched to alternatives like OTC Retaine drops (approximately $20 USD for 30 containers) or prescription alternatives like Xiidra after Restasis failed to produce results.
How Does Restasis Compare to Xiidra?
Both Restasis and Xiidra are FDA-approved prescription treatments for chronic dry eye disease that increase tear production, but they use different active ingredients, different mechanisms of action, and carry different side effect profiles that make each better suited to specific patients. So which should you choose? That depends on your diagnosis, tolerance, and how quickly you need results. The comparison below lays out the key differences.
Restasis vs. Xiidra:
| Feature | Restasis | Xiidra |
| Active ingredient | Cyclosporine 0.05% | Lifitegrast 5% |
| Approved minimum age | 16 years | 17 years |
| Drug form | Emulsion | Solution |
| Dosing frequency | Twice daily | Twice daily |
| Packaging options | Vials or multidose bottle | Single-dose vials only |
Which Works Faster for Dry Eye?
Restasis typically requires 3 to 6 months before patients notice significant improvement, as the drug must gradually modify the immune response in the lacrimal glands to restore natural tear production over time. That’s not a fast result. And here’s the thing: many patients quit before the 6-month mark, which means they never see the full potential benefit.
Xiidra uses a different mechanism, targeting LFA-1/ICAM-1 interaction to block inflammatory cells from binding to the ocular surface. Some clinical comparisons suggest Xiidra may produce earlier symptom relief in certain patients. Both drugs require consistent twice-daily use for sustained effect.
What Are the Side Effects of Restasis?
In clinical trials, ocular burning was the most commonly reported adverse reaction to Restasis, affecting 17% of patients, followed by conjunctival hyperemia, eye discharge, watery eyes, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance — most often blurring — reported in 1-5% of patients. These effects are generally temporary and resolve within hours of each dose. Is burning a dealbreaker? For many patients, yes. That 17% figure is not a small number, and it explains why so many reviews cite discomfort as the primary reason for stopping treatment.
Common Side Effects of Restasis:
- Burning sensation in the eye (17% in clinical trials)
- Increased eye redness (conjunctival hyperemia)
- Eye discharge or watery eyes
- Eye pain, itching, or stinging
- Blurry vision
- Foreign body sensation
What Are the Serious Side Effects of Restasis?
Serious side effects of Restasis include severe eye pain or burning after applying drops, swollen eyelids, and significant eye swelling, redness, severe discomfort, crusting, or drainage from the eye — all of which require immediate medical evaluation. These serious effects are uncommon in clinical practice. Still, if they appear, stop the medication and contact a doctor right away.
Eye injury and contamination risk exists when the tip of the Restasis vial or multidose bottle touches the eye or any surface. That contact can introduce bacteria or fungi to the eye. Infection from contamination can lead to serious ocular disease if not treated promptly.
Who Should Avoid Restasis?
Restasis is contraindicated in patients with known or suspected hypersensitivity to any of its ingredients, and it must not be used while contact lenses are in the eye — lenses must be removed before application and can only be reinserted 15 minutes after using the drops. These aren’t suggestions. They’re firm contraindications that apply to every patient.
Restasis is not approved for children under 16 years of age. Safety and efficacy have not been established in younger patients. Additionally, the drug didn’t increase tear production in patients already using topical anti-inflammatory drugs or tear duct plugs, so these patients are less likely to benefit.
How Long Does Restasis Take to Work?
Restasis may begin showing therapeutic effects within a few weeks, but most patients require at least 3 months before noticing meaningful improvement, and maximum benefit is typically seen only after 6 continuous months of twice-daily use. So, is that timeline normal? Yes. The drug is modifying an immune response, not masking a symptom. That kind of change takes time.
Restasis is designed for long-term use, not short-term or as-needed treatment. Patients who stop taking it generally experience a full return of dry eye symptoms. This return confirms the drug manages the condition rather than curing the underlying immune disorder responsible for it.
Restasis Treatment Timeline:
- Weeks 1-4: Begin twice-daily dosing; mild side effects such as burning are most common in this period.
- Months 1-3: Some patients notice early reduction in dryness or irritation; patience is essential.
- Months 3-6: Meaningful tear production increase becomes measurable for responding patients.
- Month 6 onward: Peak efficacy reached; continued daily use maintains the improvement.
What Results Should You Expect at 6 Months?
At 6 months, clinical trial participants using Restasis showed a statistically significant increase in Schirmer test scores compared to vehicle-treated patients, representing the peak measurable improvement in natural tear production for the drug. For patients who respond, this is when daily comfort is most noticeably better. Many describe it as the point where their eyes finally feel ‘normal.’
Individual variability is significant. Some patients achieve near-complete symptom resolution at 6 months. Others see only modest gains. The key differentiator is whether inflammation is the primary driver of the dry eye. Environmental or structural causes respond less reliably to Restasis.
How Much Does Restasis Cost?
Restasis is an expensive brand-name prescription medication whose cost varies significantly depending on insurance coverage, pharmacy location, and use of manufacturer savings programs — with out-of-pocket costs potentially reaching several hundred dollars per month without assistance. Here’s the reality: cost is one of the most common reasons patients stop treatment before seeing results.
Is there a way to reduce the cost? Yes. One patient reports paying approximately $80 USD ($80 CAD in Canada) per month using a manufacturer’s savings card — significantly lower than the full retail price. Insurance coverage ranges from 100% in some plans to high copays in others. Patients without adequate coverage often explore generics, manufacturer coupons, or compounded formulations to reduce costs.
Is Restasis Worth the Price?
For patients who respond well to Restasis, most report the cost as justified given the significant improvement in quality of life and the absence of effective OTC alternatives that address the underlying inflammatory cause of their dry eye. For non-responders, it’s a frustrating and expensive experience. The key is knowing upfront whether you’re likely to benefit.
OTC alternatives like Retaine cost approximately $20 USD for 30 containers with no prescription required. These drops provide symptomatic moisture relief but don’t address the immune-driven inflammation that drives chronic dry eye. For patients with confirmed inflammation-based dry eye, OTC options alone are typically insufficient for meaningful long-term relief.
Is Restasis FDA Approved and Legit?
Yes. Restasis received FDA approval as the first prescription treatment specifically for chronic dry eye with decreased tear production due to inflammation, classified under NDA 50-790 and manufactured by Allergan, an AbbVie company, with initial US approval for cyclosporine ophthalmic use in 1983. It’s a legitimate pharmaceutical product with a well-documented regulatory history. No scam concerns here.
Physicians broadly accept Restasis as a first-line prescription treatment for inflammation-driven keratoconjunctivitis sicca. Is the physician consensus strong? Very strong. The safety profile of cyclosporine ophthalmic emulsion is well-established across decades of clinical use. The FDA tracks post-marketing side effects through its MedWatch program at fda.gov/medwatch, and the drug’s adverse event record is publicly accessible.
Cyclosporine ophthalmic emulsion 0.05% is the only concentration FDA-approved for chronic dry eye at this strength. Restasis is available under the brand name as well as in generic form. Compounded cyclosporine in higher concentrations exists but is not FDA-approved at those strengths.
Is There a Generic Version of Restasis?
Yes. Generic cyclosporine ophthalmic emulsion 0.05% is available as a lower-cost alternative to brand-name Restasis and contains the same active ingredient at the same concentration and dosage form. Insurance plans may prefer or require the generic. Cost savings can be significant depending on the specific pharmacy and plan.
Generic versions must meet FDA bioequivalence standards, confirming they deliver the same amount of active drug to the eye in the same timeframe as the brand-name product. Some patients report slight differences in emulsion feel or tolerability. Discussing generic options with a pharmacist or prescribing doctor is the most practical first step.
Is Restasis Worth It?
Yes, for the right patient. Restasis is worth pursuing for patients with confirmed inflammation-driven chronic dry eye who haven’t achieved adequate relief from OTC lubricants, with the clearest benefit seen in patients with Sjogren’s syndrome, ocular rosacea, or other autoimmune-linked tear production problems. For these patients, Restasis addresses a cause that no OTC product can reach.
Patient success strongly correlates with the underlying diagnosis. So what’s the deciding factor? The cause of the dry eye. Patients with autoimmune or immune-mediated dry eye have the best outcomes. Patients with environmental, hormonal, or structural causes may see limited benefit and are better served by alternative treatments first.
Based on pooled review data, Restasis helps roughly 26 to 42% of users significantly. For the remaining majority, alternatives like Xiidra, Cequa, or OTC lubricating drops may provide better value with fewer side effects. A thorough evaluation by an ophthalmologist helps determine whether Restasis is the right choice before committing to a 6-month trial.
Who Is Restasis Best For?
- Patients with Sjogren’s syndrome-related dry eye
- Patients with ocular rosacea affecting tear production
- Patients with other autoimmune-linked lacrimal gland problems
- Patients who have failed multiple OTC lubricating drop regimens
- Patients with confirmed ocular surface inflammation on examination
Patients who stop Restasis due to burning or cost most commonly try Xiidra next, which uses a different molecular target and may be better tolerated for some patients. Cequa contains a higher cyclosporine concentration (0.09%) using a nanomicellar formulation, which may improve drug delivery compared to Restasis. For milder dry eye, OTC preservative-free artificial tears remain a low-cost first option before committing to a prescription treatment.
What Are the Best Alternatives to Restasis?
The best alternatives to Restasis include Xiidra (lifitegrast 5%) and Cequa (cyclosporine 0.09%), both of which use different formulations or mechanisms that may work where Restasis did not, along with OTC preservative-free artificial tears for milder inflammation-independent dry eye. Each option targets the condition differently. The right choice depends on the underlying cause and patient tolerance.
Xiidra and Cequa are both prescription-only and require a doctor’s evaluation. OTC options like Retaine cost approximately $20 USD for 30 containers with no prescription needed. An ophthalmologist can help identify which alternative fits the specific diagnosis before committing to another multi-month treatment trial.